Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Apr;17(4):35.
doi: 10.1007/s11934-016-0587-1.

Prostate Cancer Prevention: Concepts and Clinical Trials

Affiliations
Review

Prostate Cancer Prevention: Concepts and Clinical Trials

Zachary Hamilton et al. Curr Urol Rep. .

Abstract

Prevention is an important treatment strategy for diminishing prostate cancer morbidity and mortality and is applicable to both early- and late-stage disease. There are three basic classifications of cancer prevention: primary (prevention of incident disease), secondary (identification and treatment of preclinical disease), and tertiary (prevention of progression or recurrence). Based on level I evidence, 5-alpha reductase inhibitors (5-ARIs) should be considered in selected men to prevent incident prostate cancer. Level I evidence also supports the consideration of dutasteride, a 5-ARI, for tertiary prevention in active surveillance and biochemical recurrence patients. Vitamins and supplements, including selenium or vitamin E, have not been proven in clinical trials to prevent prostate cancer and in the case of Vitamin E has been found to increase the risk of incident prostate cancer. Ongoing and future trials may further elucidate the role of diet and immunotherapy for prevention of prostate cancer.

Keywords: 5-Alpha reductase inhibitors; Immunotherapy; Prostate cancer.

Similar articles

See all similar articles

Cited by 3 articles

References

    1. Eur Rev Med Pharmacol Sci. 2015;19(5):805-12 - PubMed
    1. Cancer Epidemiol Biomarkers Prev. 2008 Jan;17(1):88-94 - PubMed
    1. Cancer Immunol Immunother. 2013 Sep;62(9):1521-31 - PubMed
    1. Prostate. 2006 Jul 1;66(10):1070-5 - PubMed
    1. J Natl Cancer Inst. 2006 Aug 16;98(16):1128-33 - PubMed

LinkOut - more resources

Feedback